

Davidson, Mark

From: Davidson, Mark
Sent: Monday, August 14, 2017 11:12 AM
To: 'Rizwana Sproule'
Cc: 'Alex Babayan'; 'Nadia Agopyan'
Subject: Kite Pharm 125643 Clinical IR 8.14.17

Importance: High

Dear Dr. Sproule,

During the course of the ZUMA studies, you chose certain treating sites to be certified to administer your product. Please provide details regarding how these treating sites/hospitals were chosen, and about the certification process that these centers had to undergo. Additionally, if your product is licensed, please also provide more clarity on your proposed plan on which hospitals will be certified to administer your product in the postmarketing period.

Please respond by COB August 15, 2017.

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax: 301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."